Why the study?
How does pharmacologic therapy compare to AV node ablation in the management of symptomatic elderly patients with atrial fibrillation?
How does pharmacologic therapy compare to AV node ablation in the management of symptomatic elderly patients with atrial fibrillation?
This review provides an overview of the management of atrial fibrillation in symptomatic elderly patients, comparing pharmacologic therapy and AV node ablation.
May inform AF management choices in symptomatic elderly patients; leaves open need for randomized ablation-versus-drug trials.
Atrial fibrillation is an abnormal heart rhythm affecting the upper chambers of the heart in which uncoordinated electrical depolarizations lead to ineffective contractions. Approximately five million patients in the US have atrial fibrillation, and this number is expected to double to 10 million over the next 30 years. Advancing age is a major risk factor for the development of atrial fibrillation; new cases of atrial fibrillation are diagnosed in men over age 80 at the rate of 2% per year. Although several drugs are available for management of atrial fibrillation, the efficacy of these drugs may be limited in elderly patients. In this review, we provide an overview of management of atrial fibrillation, with special emphasis on pharmacologic therapy versus arteriovenous (AV) node ablation in symptomatic elderly patients.
No takes yet. Share an insight, caveat, or question.
Bradley et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: